Hyaluronic acid composition
Patent Information
- Application Number
- EP2023730021
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-30
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-27
AI Technical Summary
Native hyaluronic acid and its salts have a short half-life after injection, leading to limited effectiveness due to rapid degradation, and cross-linking agents used for stabilization are toxic, posing safety concerns.
A composition method involving hyaluronic acid and/or its salts combined with biologically active molecules, where an alkaline solution expands and swells hyaluronic acid molecules, allowing biologically active molecules to be encapsulated, and an acid solution adjusts pH and stereochemistry to delay their release, eliminating the need for toxic cross-linking agents.
The method achieves a sustained release of biologically active molecules, enhancing their biological activity and duration of effect while maintaining safety by avoiding toxic cross-linking agents, similar to cross-linked compositions but without their associated disadvantages.
Smart Images

Figure 000019
Abstract
Description
[0001]HYALURONIC ACID COMPOSITION The invention relates to a method for producing a composition, to a composition produced in this way, and to a use of the composition, wherein the composition contains hyaluronic acid and / or at least one salt of hyaluronic acid and at least one biologically active molecule. It is known from the prior art to inject hyaluronic acid-containing compositions into human tissue for aesthetic and therapeutic applications. Hyaluronic acid is also referred to in the literature as hyaluronan, hyaluronic acid. Hyaluronic acid is a polysaccharide formed by several disaccharide repeating units, each containing D-glucuronic acid and N-acetyl-D-glucosamine. Hyaluronic acid is found in high concentrations in the skin, in the synovial fluid, and in the vitreous humor of the eye.A person with a body weight of 70 kg has approximately 15 g of hyaluronic acid, half of which is contained in the tissue. The amount of hyaluronic acid decreases with age. In many applications, it is known to inject compositions containing native and / or chemically modified hyaluronic acid and / or its salts. The disadvantage of this is that native hyaluronic acid and / or its salts have only a short half-life after injection and degenerate and break down relatively quickly, so that the duration of the composition's effectiveness is very limited. To increase the half-life of the hyaluronic acid after injection of the composition, the hyaluronic acid and / or its salts are stabilized by cross-linking during production of the composition.However, the cross-linking agents used in this context are toxic, which compromises the safety of a composition containing cross-linked hyaluronic acid and / or its salts. Therefore, the object of the invention is to eliminate the aforementioned disadvantages of the prior art and, in particular, to produce a composition that is safer to use while still offering the advantages of stabilized hyaluronic acid and / or its salts. The same applies to the composition and its use.The object of the invention is achieved by a composition containing hyaluronic acid and / or a salt of hyaluronic acid and at least one biologically active molecule, the method comprising the following steps: - providing a solution containing hyaluronic acid and / or a salt of hyaluronic acid, - adding an alkaline solution, - adding the at least one biologically active molecule and - adding an acid solution to obtain the composition. The object of the invention is also achieved by a composition produced by the method according to the invention. Furthermore, the object of the invention is achieved by using the composition according to the invention for aesthetic and / or therapeutic application in humans and / or animals.The invention is based on the fundamental idea that the manufacturing process according to the invention eliminates the need for stabilizing additives for the hyaluronic acid and / or the hyaluronic acid salt, for example for cross-linking. The stabilizing effect is achieved within the scope of the process according to the invention by the addition of the alkaline solution causing the molecules of the hyaluronic acid and / or the hyaluronic acid salt to expand spatially, thus swelling. This allows the at least one biologically active molecule, which according to the invention is added only after the addition of the alkaline solution, to penetrate into the spaces now created between the hyaluronic acid and / or the hyaluronic acid salt.The subsequent addition of the acid solution not only ensures that the composition produced according to the invention has a desired, in particular a neutral, pH value, but the acid solution also changes the stereochemistry of the molecules of hyaluronic acid and / or the salt of hyaluronic acid in such a way that they contract again. As a result, in particular, the biologically active molecules are enclosed in the spaces between the molecules of hyaluronic acid and / or the salt of hyaluronic acid. This causes a delayed, sustained release of the biologically active molecules after application of the composition produced according to the invention, thus improving its effectiveness and, in particular, enabling a longer biological activity of the at least one biologically active molecule.The composition produced according to the invention thus has the same advantages as a composition whose hyaluronic acid and / or its salt of hyaluronic acid has been cross-linked with other additives, but without the disadvantages necessarily associated with this. The hyaluronic acid and / or the salt of hyaluronic acid can be obtained from animal sources and / or by bacterial fermentation. A physiologically acceptable salt of hyaluronic acid is preferably used as the salt of hyaluronic acid, which includes in particular the sodium salt, the calcium salt, the potassium salt, the zinc salt, and mixtures thereof. For physiological reasons, the sodium salt of hyaluronic acid is preferably used, which is also referred to as sodium hyaluronate, NaHA, or according to the international nomenclature as hyaluronan sodium. Sodium hyaluronate is stable, soluble, and membrane-permeable and therefore physiologically acceptable.The concentration of hyaluronic acid and / or the salt of hyaluronic acid can, preferably after addition of the alkaline solution, be between 5 mg / ml and 150 mg / ml, in particular between 30 mg / ml and 130 mg / ml, most preferably between 50 mg / ml and 110 mg / ml. In a further development of the invention, it can be provided that the alkaline solution comprises water and at least one hydroxide component. The water of the alkaline solution can be at least one member of the group purified water, ultrapure water, ultra-pure water and water for injection purposes. The hydroxide component can comprise an alkali metal hydroxide, in particular potassium hydroxide (KOH). The hydroxide component is preferably sodium hydroxide (NaOH), in particular with a concentration of 1 N in the alkaline solution.Embodiments of the invention can provide that the concentration of the hydroxide component in the alkaline solution is between 0.05 N and 1.5 N, in particular between 0.1 N and 1 N, preferably between 0.25 N and 1 N. After adding the alkaline solution, a certain time interval can be waited until the biologically active molecule is added. This time interval is also referred to as the solution time in the sense of the invention and can be between 5 min and 120 min, in particular between 20 min and 90 min, preferably between 30 min and 60 min. Adding the alkaline solution can comprise mixing the composition, wherein the mixing process can take place during and / or after adding the alkaline solution, which contributes to faster homogenization of the composition.Mixing can take place at room temperature and / or under pressure and / or using ultrasound signals to improve the homogenization of the composition. Preferably, the at least one biologically active molecule according to the invention induces a biological effect on skin cells, in particular fibroblasts, keratinocytes, melanocytes, and / or adipocytes. The at least one biologically active molecule is preferably selected according to the intended use of the composition according to the invention. Biologically active molecules according to the invention include comparatively large, particularly natural molecules, such as proteins, in particular cytokines, and lipids, as well as comparatively small molecules that can regulate specific signaling pathways and contribute to cell programming and / or tissue repair.According to the invention, the at least one biologically active molecule is preferably cell-permeable, non-immunogenic, and can reversibly and selectively modulate intracellular processes of target cells of the biologically active molecule. Preferably, the at least one biologically active molecule is selected from the group consisting of amino acids, amino esters, hydroxy esters, aldehydes, aldehyde derivatives, ketones containing multiple hydroxyl groups, derivatives of ketones containing multiple hydroxyl groups, cysteine, and L-cysteine. Adding the at least one biologically active molecule may comprise mixing the composition, wherein the mixing may occur during and / or after adding the at least one biologically active molecule. In this way, improved homogenization of the ingredients of the composition is achieved. The acid solution may comprise hydrochloric acid, in particular concentrated hydrochloric acid.The addition of the acid solution can comprise mixing the composition, wherein the mixing of the composition can take place during and / or after the addition of the acid solution. In this way, improved homogenization of the ingredients of the composition is achieved. According to the invention, the method can provide for the addition of at least one stabilizing agent, wherein the stabilizing agent within the meaning of the invention is preferably designed to protect the molecules of hyaluronic acid and / or the salt of hyaluronic acid from damaging influences. The stabilizing agent can comprise at least one antioxidant, in particular an antioxidant vitamin and / or a derivative of an antioxidant vitamin, in order to protect the hyaluronic acid and / or its salt contained in the composition from degeneration by free radicals.For example, the stabilizing agent comprises at least one carboxylic acid from the group of antioxidant vitamins and / or its amide. The stabilizing agent preferably comprises nicotinic acid, also known as vitamin B3, pyridine-3-carboxylic acid, or niacin, and / or its amide nicotinamide, also known as niacinamide, nicotinamide, pyridine-3-carboxamide, or niacinamide. The concentration of the at least one stabilizing agent, in particular of the at least one antioxidant, can be between 0.01 mg / ml and 60 mg / ml, preferably between 1 mg / ml and 50 mg / ml, most preferably between 5 mg / ml and 30 mg / ml. To simplify the method according to the invention, it can be provided that the at least one stabilizing agent is added together with the acid solution.Preferably, the at least one stabilizing agent is dissolved in the acid solution and in particular has a concentration between 0.05 N and 1.5 N, in particular between 0.1 N and 1 N, most preferably between 0.25 N and 1 N. The acid solution, in particular with the at least one stabilizing agent dissolved in the acid solution, is preferably added at a cooler temperature than the ambient temperature, in particular at a temperature between 1°C and 12°C, preferably between 4°C and 8°C. It has been shown that an acid solution that is cooler than the ambient temperature improves the aforementioned effect on the molecules of hyaluronic acid and / or its salt. Preferably, the composition is sterilized, in particular using heat, for example moist heat. For this purpose, autoclaving of the composition can be provided, in particular.The composition can be sterilized at a temperature above 100°C, preferably above 110°C, in particular above 120°C. In addition, the duration of the sterilization can be between 1 s and 30 min. The sterilization can have at least one sterilization cycle, wherein the sterilization cycle can be, for example, sterilization at 121°C for 20 min, at 126°C for 7 min, or at 130°C for 3 min. The hyaluronic acid and / or the salt of hyaluronic acid in the composition according to the invention can have a molecular weight between 0.01 Da and 6 MDa, in particular between 0.1 Da and 3.5 MDa. In addition, the composition according to the invention can be in the form of a hydrogel. The composition according to the invention can have a concentration of hyaluronic acid and / or its salt between 0.01 mg / ml and 60 mg / ml, in particular between 5 mg / ml and 35 mg / ml, preferably between 10 mg / ml and 25 mg / ml.In addition, the composition according to the invention can have a concentration of the at least one biologically active molecule between 0.01 mg / ml and 50 mg / ml, in particular between 1 mg / ml and 30 mg / ml, preferably between 1 mg / ml and 20 mg / ml. The composition according to the invention can have a concentration of the at least one stabilizing agent between 1 mg / ml and 60 mg / ml, in particular between 5 mg / ml and 50 mg / ml, preferably between 10 mg / ml and 30 mg / ml. The stabilizing agent can in particular be diluted in an acidic solution and in particular have a concentration between 0.05 N and 1.5 N, in particular between 0.1 N and 1 N, preferably between 0.25 N and 1 N. The composition according to the invention can be injectable, in particular filled into a syringe and / or vial.The inventive use of the composition can be for stimulating and / or promoting the regeneration of tissue, in particular skin tissue, and / or for moisturizing tissue and / or for protecting tissue and / or for stimulating hair growth. In addition, the use can be by intradermal and / or subcutaneous injection. Further advantages and features of the invention emerge from the claims and from the following description, in which an exemplary embodiment of the invention is explained in detail. Fig. 1 shows a table relating to changes in concentration over time for compositions G1 and REF1. A method according to the invention for producing a composition G1 and a method for producing a reference composition REF1 are described below.To prepare the composition G1 according to the invention, 22 g of powdered sodium hyaluronate (NaHA), which corresponds to the sodium salt of hyaluronic acid, with a molecular weight of approximately 2.1 MDa and a moisture content of 9.7%, are first weighed and prepared. 132 g of an aqueous solution of sodium hydroxide (NaOH) at a concentration of 0.25 N are then added as an alkaline solution. The powder is dissolved within 1 hour under mechanical homogenization. Subsequently, 320 g of a phosphate solution containing L-cysteine, the naturally occurring enantiomer of cysteine, is added, with L-cysteine diluted at a ratio of 1:15. The composition is then mechanically homogenized for 30 minutes.A phosphate buffer solution cooled to a temperature between 4°C and 8°C is then added such that the composition has a pH of 7.2, followed by mechanical homogenization. A phosphate solution containing 30 g of nicotinamide, which corresponds to the amide of nicotinic acid, is added to this composition, followed by mechanical homogenization for a period of 2 hours. The resulting gel-like composition according to the invention is designated G1. The inventive composition G1 has a hyaluronic acid concentration of 10 mg / g, an L-cysteine concentration of 10 mg / g, and a nicotinamide concentration of 15 mg / g, each based on the total composition. The inventive composition G1 is placed in a borosilicate glass vial and autoclaved at a temperature of 121°C for 20 minutes.To prepare the reference composition REF1, 22 g of powdered sodium hyaluronate (NaHA) with a molecular weight of approximately 2.1 MDa and a moisture content of 9.7% are weighed and prepared. 20 g of L-cysteine and 30 g of nicotinamide are added. A phosphate buffer solution is then added, and the composition is mechanically homogenized for 3.5 hours. The resulting gel-like reference composition is designated REF1 and has a hyaluronic acid concentration of 10 mg / g, an L-cysteine concentration of 10 mg / g, and a nicotinamide concentration of 15 mg / g, each based on the total composition. The reference composition REF1 is placed in a borosilicate glass vial and autoclaved at 121°C for 20 minutes.The concentrations of hyaluronic acid, L-cysteine, and nicotinamide in the composition G1 produced according to the invention correspond to the corresponding concentrations of the reference composition REF1, whereby the composition G1 according to the invention differs from the reference composition REF1 in its manufacturing process. In the following, according to Fig. 1, the release dynamics of L-cysteine and nicotinamide are investigated, on the one hand, for the composition G1 produced according to the invention and, on the other hand, for the reference composition REF1. It will be shown that the release dynamics of the two compositions G1 and REF1 differ, which is primarily due to the different manufacturing processes.5 g of the composition G1 prepared according to the invention and 5 g of the reference composition REF1 are each placed in a small dialysis bag in 20 g of a saline or NaCl solution, with dialysis being carried out at various time intervals. After the time periods designated "t" in the first line of Fig. 1, the dialysis is stopped, and the compositions G1 and REF1 are each homogenized with a spatula, and the concentrations of L-cysteine and nicotinamide are each determined by UV spectroscopy. The concentrations thus determined for the compositions G1 and REF1 are shown in the rows of Fig. 1, with the concentrations each corresponding to the remaining proportion of the components mentioned in Fig. 1 relative to the original concentration of the components before the start of dialysis. The concentrations given in Fig. 1 are therefore to be understood as relative concentrations.The concentrations are determined as a weight percent, % (w / w). The first line of Fig. 1 shows the different times at which dialysis was performed. The second line shows the concentrations of L-cysteine ("L-cysteine") determined at the times stated in the first line for the composition G1 produced using the method according to the invention, while the third line shows the concentrations of L-cysteine for the reference composition REF1. The fourth line of Fig. 1 shows the concentrations of nicotinamide ("niacinamide") at the stated times for the composition G1 produced according to the invention, and the fifth line shows the concentrations of nicotinamide for the reference composition REF1. It should be noted that for both compositions G1 and REF1, an almost complete release of both L-cysteine and nicotinamide occurs after 8 hours at the latest.However, there are clear differences in the release dynamics between compositions G1 and REF1, which are associated with a considerable advantage in clinical application for composition G1 produced according to the invention. Comparing the second line with the third line in Fig. 1, it can be seen that after 1.5 hours, composition G1 still has an L-cysteine concentration of 0.63, i.e. 63%, while the L-cysteine concentration of the reference composition REF1 has fallen to 0.25 at the same time, more than half compared to composition G1. After 4 hours, composition G1 has an L-cysteine concentration of 0.38, which is a factor of 4 higher than the L-cysteine concentration of 0.08 of the reference composition REF1 at the same time.In the composition G1 produced according to the invention, the release of L-cysteine as a biologically active molecule is therefore significantly delayed compared to the reference composition REF1. One explanation for this is that the alkaline solution initially causes the hyaluronic acid chains to expand, after which the cooled hydrochloric acid added after the addition of L-cysteine as a biologically active molecule to neutralize the composition causes steric hindrance to the hyaluronic acid molecules, causing them to be contracted or compressed by the hydrochloric acid, thereby enclosing the L-cysteine molecules between them for longer. The result is the delayed release of L-cysteine. With regard to nicotinamide, the concentration curves according to Fig.1 shows that after 4 hours, the nicotinamide concentrations in both compositions G1 and REF1 had fallen to almost 0; almost all of the nicotinamide had been released after this time. In comparison, it is noticeable that after 1.5 hours, the nicotinamide concentration of composition G1 fell more quickly, to a value of 0.17, than in the case of the reference composition REF1, which had a nicotinamide concentration of 0.23 after 1.5 hours. It is possible that the steric hindrance in nicotinamide is not significant, or only to a very small extent, because nicotinamide is only added at the end of the process during the preparation of composition G1, specifically after the hyaluronic acid molecules have contracted, so that the nicotinamide molecules are not subject to any delayed release dynamics.
Claims
Claims 1. A process for producing a composition containing hyaluronic acid and / or a salt of hyaluronic acid, as well as at least one biologically active molecule, wherein the process comprises the following steps: - providing a solution containing hyaluronic acid and / or a salt of hyaluronic acid, - adding an alkaline solution, - adding the at least one biologically active molecule, and - adding an acid solution while maintaining the composition.
2. The process according to claim 1, characterized in that the alkaline solution comprises water and a hydroxide component, in particular an alkali metal hydroxide.
3. The process according to claim 1 or 2, characterized in that the at least one biologically active molecule exerts a biological effect on skin cells, in particular fibroblasts, keratinocytes, melanocytes, and / or adipocytes.
4. A method according to any one of claims 1 to 3, characterized in that the at least one biologically active molecule is selected from the group consisting of amino acids, amino esters, hydroxy esters, aldehydes, derivatives of aldehydes, ketones containing multiple hydroxyl groups, derivatives of ketones containing multiple hydroxyl groups, cysteine, and L-cysteine.
5. A method according to any one of claims 1 to 4, characterized in that the acid solution comprises concentrated hydrochloric acid.
6. A method according to any one of claims 1 to 5, characterized in that the method provides for the addition of at least one stabilizing agent.
7. A method according to claim 6, characterized in that the at least one stabilizing agent comprises at least one antioxidant, in particular an antioxidant vitamin.
8. A method according to any one of claims 6 or 7, characterized in that the at least one stabilizing agent is added together with the acid solution. 9.Method according to claim 8, characterized in that the at least one stabilizing agent is dissolved in the acid solution and in particular has a concentration between 0.05 N and 1.5 N, especially between 0.1 N and 1 N, preferably between 0.25 N and 1 N.
10. A method according to any one of claims 1 to 9, characterized in that the composition is sterilized.
11. A composition prepared according to a method of claims 1 to 10.
12. Use of a composition according to claim 11 for aesthetic and / or therapeutic applications in humans and / or animals.
13. Use according to claim 12, characterized in that the use is for stimulating and / or promoting the regeneration of tissue, in particular skin tissue, and / or for moisturizing tissue and / or for protecting tissue and / or for stimulating hair growth.
14. Use according to any one of claims 12 or 13, characterized in that the use is by intradermal and / or subcutaneous injection.
